Chen Jergin, Lee R Jeffrey, Tsodikov Alex, Smith Lynn, Gaffney David K
Department of Radiation Oncology, University of Utah, Salt Lake City, UT 84132, USA.
Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1474-9. doi: 10.1016/j.ijrobp.2003.09.018.
To determine whether the risk of secondary breast cancer after radiotherapy (RT) for Hodgkin's disease is greater among women who underwent RT around time of pregnancy.
The records of 382 women treated with RT for Hodgkin's disease were reviewed and divided into those who received RT around the time of pregnancy and those who were not pregnant. Comparisons of the overall incidence, actuarial rates, and latency to breast cancer between the two groups were made. Multivariate Cox regression modeling was performed to determine possible contributing factors.
Of the 382 women, 14 developed breast cancer (3.7%). The increase in the overall incidence (16.0% vs. 2.3%, p = 0.0001) and the actuarial rate of breast cancer among the women in the pregnant group (p = 0.011) was statistically significant. The women treated around the time of pregnancy had a 10- and 15-year actuarial rate of breast cancer of 6.7% and 32.6%, respectively. The 10-year and 15-year actuarial rate for the nonpregnant women was 0.4% and 1.7%, respectively. The median latency from RT to the diagnosis of breast cancer was 13.1 and 18.9 years for women in the pregnant and nonpregnant groups, respectively. In the multivariate analysis, pregnancy around the time of RT was the only variable associated with an increased risk of breast cancer. The risk was dependent on the length of time from pregnancy to RT, with women receiving RT during pregnancy and within 1 month of pregnancy having an increased risk of breast cancer compared with nonpregnant women and women irradiated later than 1 month after pregnancy (hazard ratio, 22.49; 95% confidence interval, 5.56-90.88; p <0.001).
The results of this study indicate that the risk of breast cancer after RT is greater with irradiation around the time of pregnancy. This suggests that pregnancy is a time of increased sensitivity of breast tissue to the carcinogenic effects of radiation. Because of the small sample size and limited follow-up, additional studies are recommended to confirm these findings.
确定接受放疗(RT)治疗霍奇金淋巴瘤的女性中,在孕期前后接受放疗者患继发性乳腺癌的风险是否更高。
回顾了382例接受放疗治疗霍奇金淋巴瘤的女性记录,并将其分为孕期前后接受放疗者和未怀孕者。对两组之间乳腺癌的总体发病率、精算率和潜伏期进行了比较。进行多变量Cox回归建模以确定可能的影响因素。
382例女性中,14例患乳腺癌(3.7%)。怀孕组女性乳腺癌的总体发病率(16.0%对2.3%,p = 0.0001)和精算率(p = 0.011)的增加具有统计学意义。孕期前后接受放疗的女性患乳腺癌的10年和15年精算率分别为6.7%和32.6%。未怀孕女性的10年和15年精算率分别为0.4%和1.7%。怀孕组和未怀孕组女性从放疗到乳腺癌诊断的中位潜伏期分别为13.1年和18.9年。在多变量分析中,放疗前后怀孕是与乳腺癌风险增加相关的唯一变量。风险取决于从怀孕到放疗的时间长度,与未怀孕女性和怀孕1个月后接受放疗的女性相比,孕期和怀孕1个月内接受放疗的女性患乳腺癌的风险增加(风险比,22.49;95%置信区间,5.56 - 90.88;p <0.001)。
本研究结果表明,孕期前后接受放疗后患乳腺癌的风险更高。这表明孕期是乳腺组织对辐射致癌作用敏感性增加的时期。由于样本量小和随访有限,建议进行更多研究以证实这些发现。